Design of Enabling-Regenerative Materials
Priority AxisTechnological and Social Innovation
University of Brighton
Project budget2 724 815 €
ERDF amount1 634 889 €
DERMA will address the common challenge of improving the quality of life of the increasing elderly population of the 2 Seas area. By 2025, more than 20% of Europeans will be 65 or older, with a large increase in those over 80. We will tackle the problem of advanced age (or illness)-associated inflammation, infection and ulceration of the skin which costs the EU €6.5 billion per year. Dermal ulcers are a source of physical discomfort, can lead to further medical complications, and can liberate offensive odours that are distressing to the patient and may lead to social isolation and depression.
The objective of DERMA is to develop new interventions for the management and treatment of dermal ulcers and related skin conditions, including stomas. By addressing market and patient needs, as identified by our Observer Partners (OPs), the project will deliver advanced new technologies (incorporating marine sourced biopolymers) ready for exploitation by industry to manufacture improved products for the treatment of patients. It is expected that these enabling technologies will provide cost savings to the EU by improving the efficiency and success of wound management by healthcare providers.
Technologies with increased readiness levels for the treatment of dermal ulcers, peristomal inflammation, and related conditions in response to identified market and patient needs.
- a dressing for wound odour and infection control (TRL 3 to 5);
- a dressing with a diagnostic indicator of early wound healing status (TRL 3 to 5).
Beneficiaries will be elderly patients, cancer patients, diabetics, ostomates (all through improved treatment and quality of life), healthcare providers (better treatment options and cost savings), regional industry (boost for innovation, blue economy and sales).
Cross border approach
The problem of dermal pathologies of the elderly is a shared one of the 2 Seas region. To tackle effectively this growing problem, we need new improved technologies and management options to reduce costs and improve outcomes. This can occur by pooling the cross-border expertise of our consortium, in the field of wound care, towards critical mass for technological innovation. This will promote product development by 2 Seas industries - encouraged by dissemination to our regional SME networks. Ultimately, this will improve the quality of life of the elderly population across borders.
University of Portsmouth
Blond McIndoe Research Foundation (Queen Victoria Hospital) (BMRF)
Fédération de recherche « Biomatériaux et Dispositifs Médicaux Fonctionnalisés (BDMF)
Welland Medical Limited (WM)